The global pharmacovigilance market size is calculated at USD 10.36 billion in 2025 and is forecasted to reach around USD 22.25 billion by 2034, accelerating at a CAGR of 8.88% from 2025 to 2034. The North America pharmacovigilance market size surpassed USD 2.96 billion in 2024 and is expanding at a CAGR of 8.90% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Process Flow Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmacovigilance Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmacovigilance Market, by Clinical Trial Phase Type
8.1.1. Preclinical Phase I
8.1.1.1. Market Revenue and Forecast
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast
9.1. Pharmacovigilance Market, by Service Provider Type
9.1.1. In-house
9.1.1.1. Market Revenue and Forecast
9.1.2. Contract Outsourcing
9.1.2.1. Market Revenue and Forecast
10.1. Pharmacovigilance Market, by End User Type
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Pharmaceutical Companies
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. Pharmacovigilance Market, by Therapeutic Area Type
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Neurology
11.1.2.1. Market Revenue and Forecast
11.1.3. Cardiology
11.1.3.1. Market Revenue and Forecast
11.1.4. Respiratory Systems
11.1.4.1. Market Revenue and Forecast
11.1.5. Others
11.1.5.1. Market Revenue and Forecast
12.1. Pharmacovigilance Market, by Type
12.1.1. Spontaneous Reporting
12.1.1.1. Market Revenue and Forecast
12.1.2. Intensified ADR Reporting
12.1.2.1. Market Revenue and Forecast
12.1.3. Targeted Spontaneous Reporting
12.1.3.1. Market Revenue and Forecast
12.1.4. Cohort Event Monitoring
12.1.4.1. Market Revenue and Forecast
12.1.5. EHR Mining
12.1.5.1. Market Revenue and Forecast
13.1. Pharmacovigilance Market, by Service Provider Type
13.1.1. Case Data Management
13.1.1.1. Market Revenue and Forecast
13.1.2. Signal Detection
13.1.2.1. Market Revenue and Forecast
13.1.3. Risk Management System
13.1.3.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Clinical Trial Phase
14.1.2. Market Revenue and Forecast, by Service Provider
14.1.3. Market Revenue and Forecast, by End User
14.1.4. Market Revenue and Forecast, by Therapeutic Area
14.1.5. Market Revenue and Forecast, by Type
14.1.6. Market Revenue and Forecast, by Process Flow
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Clinical Trial Phase
14.1.7.2. Market Revenue and Forecast, by Service Provider
14.1.7.3. Market Revenue and Forecast, by End User
14.1.7.4. Market Revenue and Forecast, by Therapeutic Area
14.1.8. Market Revenue and Forecast, by Type
14.1.8.1. Market Revenue and Forecast, by Process Flow
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Clinical Trial Phase
14.1.9.2. Market Revenue and Forecast, by Service Provider
14.1.9.3. Market Revenue and Forecast, by End User
14.1.9.4. Market Revenue and Forecast, by Therapeutic Area
14.1.10. Market Revenue and Forecast, by Type
14.1.11. Market Revenue and Forecast, by Process Flow
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Clinical Trial Phase
14.2.2. Market Revenue and Forecast, by Service Provider
14.2.3. Market Revenue and Forecast, by End User
14.2.4. Market Revenue and Forecast, by Therapeutic Area
14.2.5. Market Revenue and Forecast, by Type
14.2.6. Market Revenue and Forecast, by Process Flow
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Clinical Trial Phase
14.2.8.2. Market Revenue and Forecast, by Service Provider
14.2.8.3. Market Revenue and Forecast, by End User
14.2.9. Market Revenue and Forecast, by Therapeutic Area
14.2.10. Market Revenue and Forecast, by Type
14.2.10.1. Market Revenue and Forecast, by Process Flow
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Clinical Trial Phase
14.2.11.2. Market Revenue and Forecast, by Service Provider
14.2.11.3. Market Revenue and Forecast, by End User
14.2.12. Market Revenue and Forecast, by Therapeutic Area
14.2.13. Market Revenue and Forecast, by Type
14.2.14. Market Revenue and Forecast, by Process Flow
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Clinical Trial Phase
14.2.15.2. Market Revenue and Forecast, by Service Provider
14.2.15.3. Market Revenue and Forecast, by End User
14.2.15.4. Market Revenue and Forecast, by Therapeutic Area
14.2.16. Market Revenue and Forecast, by Type
14.2.16.1. Market Revenue and Forecast, by Process Flow
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Clinical Trial Phase
14.2.17.2. Market Revenue and Forecast, by Service Provider
14.2.17.3. Market Revenue and Forecast, by End User
14.2.17.4. Market Revenue and Forecast, by Therapeutic Area
14.2.18. Market Revenue and Forecast, by Type
14.2.18.1. Market Revenue and Forecast, by Process Flow
14.3. APAC
14.3.1. Market Revenue and Forecast, by Clinical Trial Phase
14.3.2. Market Revenue and Forecast, by Service Provider
14.3.3. Market Revenue and Forecast, by End User
14.3.4. Market Revenue and Forecast, by Therapeutic Area
14.3.5. Market Revenue and Forecast, by Type
14.3.6. Market Revenue and Forecast, by Process Flow
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Clinical Trial Phase
14.3.7.2. Market Revenue and Forecast, by Service Provider
14.3.7.3. Market Revenue and Forecast, by End User
14.3.7.4. Market Revenue and Forecast, by Therapeutic Area
14.3.8. Market Revenue and Forecast, by Type
14.3.9. Market Revenue and Forecast, by Process Flow
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Clinical Trial Phase
14.3.10.2. Market Revenue and Forecast, by Service Provider
14.3.10.3. Market Revenue and Forecast, by End User
14.3.10.4. Market Revenue and Forecast, by Therapeutic Area
14.3.11. Market Revenue and Forecast, by Type
14.3.11.1. Market Revenue and Forecast, by Process Flow
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Clinical Trial Phase
14.3.12.2. Market Revenue and Forecast, by Service Provider
14.3.12.3. Market Revenue and Forecast, by End User
14.3.12.4. Market Revenue and Forecast, by Therapeutic Area
14.3.12.5. Market Revenue and Forecast, by Type
14.3.12.6. Market Revenue and Forecast, by Process Flow
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Clinical Trial Phase
14.3.13.2. Market Revenue and Forecast, by Service Provider
14.3.13.3. Market Revenue and Forecast, by End User
14.3.13.4. Market Revenue and Forecast, by Therapeutic Area
14.3.13.5. Market Revenue and Forecast, by Type
14.3.13.6. Market Revenue and Forecast, by Process Flow
14.4. MEA
14.4.1. Market Revenue and Forecast, by Clinical Trial Phase
14.4.2. Market Revenue and Forecast, by Service Provider
14.4.3. Market Revenue and Forecast, by End User
14.4.4. Market Revenue and Forecast, by Therapeutic Area
14.4.5. Market Revenue and Forecast, by Type
14.4.6. Market Revenue and Forecast, by Process Flow
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Clinical Trial Phase
14.4.7.2. Market Revenue and Forecast, by Service Provider
14.4.7.3. Market Revenue and Forecast, by End User
14.4.7.4. Market Revenue and Forecast, by Therapeutic Area
14.4.8. Market Revenue and Forecast, by Type
14.4.9. Market Revenue and Forecast, by Process Flow
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Clinical Trial Phase
14.4.10.2. Market Revenue and Forecast, by Service Provider
14.4.10.3. Market Revenue and Forecast, by End User
14.4.10.4. Market Revenue and Forecast, by Therapeutic Area
14.4.11. Market Revenue and Forecast, by Type
14.4.12. Market Revenue and Forecast, by Process Flow
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Clinical Trial Phase
14.4.13.2. Market Revenue and Forecast, by Service Provider
14.4.13.3. Market Revenue and Forecast, by End User
14.4.13.4. Market Revenue and Forecast, by Therapeutic Area
14.4.13.5. Market Revenue and Forecast, by Type
14.4.13.6. Market Revenue and Forecast, by Process Flow
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Clinical Trial Phase
14.4.14.2. Market Revenue and Forecast, by Service Provider
14.4.14.3. Market Revenue and Forecast, by End User
14.4.14.4. Market Revenue and Forecast, by Therapeutic Area
14.4.14.5. Market Revenue and Forecast, by Type
14.4.14.6. Market Revenue and Forecast, by Process Flow
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Clinical Trial Phase
14.5.2. Market Revenue and Forecast, by Service Provider
14.5.3. Market Revenue and Forecast, by End User
14.5.4. Market Revenue and Forecast, by Therapeutic Area
14.5.5. Market Revenue and Forecast, by Type
14.5.6. Market Revenue and Forecast, by Process Flow
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Clinical Trial Phase
14.5.7.2. Market Revenue and Forecast, by Service Provider
14.5.7.3. Market Revenue and Forecast, by End User
14.5.7.4. Market Revenue and Forecast, by Therapeutic Area
14.5.8. Market Revenue and Forecast, by Type
14.5.8.1. Market Revenue and Forecast, by Process Flow
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Clinical Trial Phase
14.5.9.2. Market Revenue and Forecast, by Service Provider
14.5.9.3. Market Revenue and Forecast, by End User
14.5.9.4. Market Revenue and Forecast, by Therapeutic Area
14.5.9.5. Market Revenue and Forecast, by Type
14.5.9.6. Market Revenue and Forecast, by Process Flow
15.1. ICON Plc
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Pharmaceutical Product Development LLC
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Parexel International Corporation
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. IQVIA
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Quanticate
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Bioclinica
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Covance Inc.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Accenture Plc
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. IBM Corporation
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Novartis
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample